<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02618603</url>
  </required_header>
  <id_info>
    <org_study_id>2016137443</org_study_id>
    <secondary_id>2016137443</secondary_id>
    <nct_id>NCT02618603</nct_id>
  </id_info>
  <brief_title>Botulinum Toxin A for Shoulder Pain After Stroke</brief_title>
  <official_title>The Effectiveness of Ultrasound Guided Sub-acromial Bursa Injection With Botulinum Toxin A in for Refractory Shoulder Pain After Stroke.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Sir Run Run Shaw Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Sir Run Run Shaw Hospital</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Shoulder pain after stroke is a very common, causing significant morbidity disease.
      Subacromial and subdeltoid (SASD) bursitis are common causes of pain or disability of the
      shoulder joint in stroke patients. Traditional therapeutic approaches for the shoulder pain
      therapy including pharmacotherapy, injection therapy, physical therapy, and behavioural
      modification. Unfortunately, these therapy methods may not be effective in many patients and
      long term benefit after treatment is transient, the outcomes may also be incomplete or
      non-existent. Botulinum toxin A (BoNT-A) is a neurotoxin that can inhibit not only the
      acetylcholine at the neuromuscular junctions but also other neurotransmitters such as
      glutamate, substance P and calcitonin gene related peptide, all of which have been indicated
      in pain transmission. Despite the therapeutic benefit of BTX in alleviating painful muscle
      spasms, its efficacy in SASD bursitis conditions is less clear. So we perform this study to
      examine the efficacy of ultrasound guided SASD injection with BoNT-A in reducing refractory
      shoulder pain after stroke.
    </textblock>
  </brief_summary>
  <overall_status>Not yet recruiting</overall_status>
  <start_date>February 2016</start_date>
  <completion_date type="Anticipated">December 2018</completion_date>
  <primary_completion_date type="Anticipated">June 2018</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Triple (Participant, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change from baseline of pain score (Numeric Rating Scale, NRS)</measure>
    <time_frame>The outcome will be undertaken at weeks 0 (baseline), 1,2,4,8, and 12 weeks after injection.</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Passive and/or active shoulder range of motion.</measure>
    <time_frame>The outcome will be undertaken at weeks 0 (baseline), 1,2,4,8, and 12 weeks after injection.</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from baseline of should muscle modified Ashworth scale assess (MAS)</measure>
    <time_frame>The outcome will be undertaken at weeks 0 (baseline), 1,2,4,8, and 12 weeks after injection.</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">50</enrollment>
  <condition>Stroke</condition>
  <condition>Pain</condition>
  <arm_group>
    <arm_group_label>BoNT-A treatment group</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Ultrasound guided sub-acromial bursa injection with BoNT-A (100 u);</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Triamcinolone acetonide treatment group</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Ultrasound guided sub-acromial bursa injection with Triamcinolone acetonide (40mg)+1% Lidocaine 2 ml;</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Botulinum toxin A</intervention_name>
    <arm_group_label>BoNT-A treatment group</arm_group_label>
    <other_name>BoNT-A</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Triamcinolone Acetonide</intervention_name>
    <arm_group_label>Triamcinolone acetonide treatment group</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Stroke patients with pain around the shoulder or lateral deltoid area and deteriorated
             during active or passive overhead activity;

          2. Neer and/or Hawkins tests (+);

          3. NRS&gt;5 at rest;

          4. Symptoms lasted for at least for 2 months and were unresponsive to analgesic
             medication or physical therapy for 1 month.

          5. Subjects voluntarily sign the informed consent.

          6. Age between 18 and 80 years old. -

        Exclusion Criteria:

          1. Received earlier subacromial injections of corticosteroids or botulinuim toxin in the
             last 6 months;

          2. Shoulder fracture, glenohumeral osteoarthritis, bone tumors or osteonecrosis in plain
             radiographs.

          3. Known allergy or sensitivity to study medication or its components.

          4. Infection or dermatological condition at the injection sites.

          5. Any medical condition that may put the subject at increased risk with exposure ,
             including diagnosed myasthenia gravis, Eaton-Lambert syndrome, amyotrophic lateral
             sclerosis, or any other disorder that might have interfered with neuromuscular
             function.

          6. QTc criteria: QTc ≥ 450 millisecond (msec) or≥480msec for subjects with Bundle Branch
             Block-values based on either single electrocardiogram (ECG) values or triplicate ECG
             averaged QTc values obtained over a brief recording period

          7. Liver function tests: aspartate aminotransferase (AST) and alanine aminotransferase
             (ALT) ≥2xULN; alkaline phosphatase and bilirubin ＞1.5xULN (isolated bilirubin &gt;1.5ULN
             is acceptable if bilirubin is fractionated and direct bilirubin &lt;35%).

          8. Concurrent use of aminoglycoside antibiotics or other agents that might interfere with
             neuromuscular function.

          9. Patients with severe cognitive impairment or neurological diseases affecting the
             implementation or evaluation of the test, and drug-dependent patients.

         10. Presence of clinically unstable severe cardiovascular, renal or respiratory disease

         11. Researchers believe there are other factors unfit to participate in this study of
             patients.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>TAO WU, MD</last_name>
    <phone>86 571 86006054</phone>
    <email>wutao1880@163.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>JIANHUA LI, MD</last_name>
    <phone>86 571 86006054</phone>
    <email>zjdxsyfkfk@126.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Sir Run Run Shaw Hospital, Medical College of Zhejiang University</name>
      <address>
        <city>Hang Zhou</city>
        <state>Zhejiang</state>
        <zip>310016</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <results_reference>
    <citation>Lee JH, Lee SH, Song SH. Clinical effectiveness of botulinum toxin type B in the treatment of subacromial bursitis or shoulder impingement syndrome. Clin J Pain. 2011 Jul-Aug;27(6):523-8. doi: 10.1097/AJP.0b013e31820e1310.</citation>
    <PMID>21368663</PMID>
  </results_reference>
  <results_reference>
    <citation>McMahon HT, Foran P, Dolly JO, Verhage M, Wiegant VM, Nicholls DG. Tetanus toxin and botulinum toxins type A and B inhibit glutamate, gamma-aminobutyric acid, aspartate, and met-enkephalin release from synaptosomes. Clues to the locus of action. J Biol Chem. 1992 Oct 25;267(30):21338-43.</citation>
    <PMID>1356988</PMID>
  </results_reference>
  <results_reference>
    <citation>Bach-Rojecky L, Salković-Petrisić M, Lacković Z. Botulinum toxin type A reduces pain supersensitivity in experimental diabetic neuropathy: bilateral effect after unilateral injection. Eur J Pharmacol. 2010 May 10;633(1-3):10-4. doi: 10.1016/j.ejphar.2010.01.020. Epub 2010 Feb 1.</citation>
    <PMID>20123097</PMID>
  </results_reference>
  <results_reference>
    <citation>Hsieh LF, Hsu WC, Lin YJ, Wu SH, Chang KC, Chang HL. Is ultrasound-guided injection more effective in chronic subacromial bursitis? Med Sci Sports Exerc. 2013 Dec;45(12):2205-13. doi: 10.1249/MSS.0b013e31829b183c.</citation>
    <PMID>23698243</PMID>
  </results_reference>
  <results_reference>
    <citation>Wu T, Song HX, Dong Y, Li JH. Ultrasound-guided versus blind subacromial-subdeltoid bursa injection in adults with shoulder pain: A systematic review and meta-analysis. Semin Arthritis Rheum. 2015 Dec;45(3):374-8. doi: 10.1016/j.semarthrit.2015.05.011. Epub 2015 May 21. Review.</citation>
    <PMID>26590864</PMID>
  </results_reference>
  <results_reference>
    <citation>Wu T, Fu Y, Song HX, Ye Y, Dong Y, Li JH. Effectiveness of Botulinum Toxin for Shoulder Pain Treatment: A Systematic Review and Meta-Analysis. Arch Phys Med Rehabil. 2015 Dec;96(12):2214-20. doi: 10.1016/j.apmr.2015.06.018. Epub 2015 Jul 17. Review.</citation>
    <PMID>26189200</PMID>
  </results_reference>
  <verification_date>November 2015</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>November 27, 2015</study_first_submitted>
  <study_first_submitted_qc>November 27, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">December 1, 2015</study_first_posted>
  <last_update_submitted>November 27, 2015</last_update_submitted>
  <last_update_submitted_qc>November 27, 2015</last_update_submitted_qc>
  <last_update_posted type="Estimate">December 1, 2015</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Sir Run Run Shaw Hospital</investigator_affiliation>
    <investigator_full_name>TAO WU</investigator_full_name>
    <investigator_title>MD</investigator_title>
  </responsible_party>
  <keyword>Stroke</keyword>
  <keyword>Should pain</keyword>
  <keyword>Botulinum Toxin</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Stroke</mesh_term>
    <mesh_term>Shoulder Pain</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Botulinum Toxins</mesh_term>
    <mesh_term>Botulinum Toxins, Type A</mesh_term>
    <mesh_term>onabotulinumtoxinA</mesh_term>
    <mesh_term>abobotulinumtoxinA</mesh_term>
    <mesh_term>incobotulinumtoxinA</mesh_term>
    <mesh_term>Triamcinolone hexacetonide</mesh_term>
    <mesh_term>Triamcinolone</mesh_term>
    <mesh_term>Triamcinolone Acetonide</mesh_term>
    <mesh_term>Triamcinolone diacetate</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

